Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.49 |
| ▸ | CLPP | Q16740 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879774 | 1.00 | GRM5 (0.49) | GRM5CLPPMEN1KMT2AATM | |
| SCHEMBL599809 | 0.92 | GRM5 (0.47) | GRM5CLPPHSD11B1 | |
| SCHEMBL599528 | 0.92 | GRM5 (0.50) | GRM5CLPPMEN1KMT2AATM | |
| SCHEMBL600389 | 0.90 | GRM5 (0.40) | GRM5CLPPHSD11B1 | |
| SCHEMBL30795442 | 0.88 | GRM5 (0.40) | GRM5CLPPHSD11B1 | |
| SCHEMBL601066 | 0.88 | GRM5 (0.40) | GRM5CLPPHSD11B1 | |
| SCHEMBL30795726 | 0.87 | HSD11B1 (0.52) | GRM5HSD11B1 | |
| SCHEMBL600170 | 0.87 | HSD11B1 (0.52) | GRM5HSD11B1 | |
| SCHEMBL600581 | 0.87 | GRM5 (0.40) | GRM5HSD11B1 | |
| SCHEMBL600727 | 0.86 | GRM5 (0.42) | GRM5HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421370-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | Merck Sharp & Dohme Corp. (US) | 2012-02-29 | — | — | EP | claimed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | claimed |
| WO-2010124055-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-28 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | MERCER SWATI P (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040998-A1 | 2-ALKYL PIPERIDINE MGLUR5 RECEPTOR MODULATORS | GRM5, GRIK5, GRM2 | GRM5 1/4885CLPP 4334/4885MEN1 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.